Skip to main content
. 2019 Apr 11;15:66–78. doi: 10.1016/j.isci.2019.04.011

Figure 5.

Figure 5

The Immunogenicity of hESC-MSCs with Day0, Day1, and Day3 hESC-MSCs

(A) PBMC proliferation rates with Day0, Day1, or Day3 hESC-MSC stimulation were compared by flow cytometry analysis. The FL1 subset indicates the non-proliferated PBMCs; the FL1 subset-1, FL1 subset-2, and FL1 subset-3 indicate the proliferated PBMCs; the PBMCs in later subset proliferate more times than the PBMCs in the former subset.

(B) PBMC proliferation rates with Day0, Day1, or Day3 hESC-MSC stimulation were quantified based on flow cytometry analysis. Data are shown as means ± SEM.

(C) Humanized mice imaging with Day0, Day1, or Day3 hESC-MSC injection after 2 weeks.

(D) The quantification analysis of Day0, Day1, or Day3 hESC-MSC immunofluorescence retained in humanized mice. Data are shown as means ± SEM.

(E) The footpad thickness of humanized mice with Day0, Day1, or Day3 hESC-MSC challenge. Data are shown as means ± SEM.

(F) The H&E staining of humanized mice footpads with Day0, Day1, or Day3 hESC-MSC challenge. The black arrows indicate the infiltrated lymphocytes in the footpad. Scale bar, 200 μm.